Drug intelligence / Profile preview

spiramycin embonate

Development stage: Unknown
Lead developer: Wuxi Fortune Pharmaceutical
Modality: Small Molecules
Administration: Oral, Intramuscular

Overview

Spiramycin embonate is the embonate (pamoate) salt of spiramycin, a 16-membered macrolide antibiotic produced by *Streptomyces ambofaciens*. It functions by binding to the 50S subunit of the bacterial ribosome, specifically at the 23S rRNA, which inhibits protein synthesis by blocking the translocation process. This antibiotic is primarily utilized in veterinary medicine for the treatment of respiratory and enteric infections in livestock and poultry caused by Gram-positive bacteria, mycoplasma, and certain Gram-negative organisms. Wuxi Fortune Pharmaceutical produces spiramycin embonate as an active pharmaceutical ingredient (API) for use in various formulations.

Other names: spiramycin embonatespiramycin pamoate

Targets

Bacterial 50S ribosomal subunit

Beyond the preview

Go deeper on spiramycin embonate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on spiramycin embonate.

Explore the full profile